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A B S T R A C T
Suppression of the renin-angiotensin system (RAS) has proven efficacy not only in 
the treatment of hypertension, but it also greatly benefits and protects patients with 
ischemic cardiomyopathy and heart failure. This inhibition not only leads to symp-
tomatic and functional improvement but it also prolongs life. The role of angiotensin 
inhibition in cardiovascular disease is herein briefly discussed.
R E N I N - A N G I O T E N S I N  S Y S T E M  A N D  H Y P E R T E N S I O N
The renin-angiotensin system (RAS) was extensively investigated and character-
ized throughout the first half of the 20th century. However, its contribution to the 
maintenance of high blood pressure in essential hypertension and to the development 
of hypertensive cardiac complications remained under debate until the advent of the 
first pharmacologic probes capable of blocking its actions, namely the angiotensin 
receptor blocker (ARB) saralasin and the angiotensin-converting enzyme inhibitor 
(ACEI) teprotide in the early 1970’s.1,2 Using these probes, we could demonstrate that 
even in normal-renin and low-renin hypertension, blockade of the RAS produced a 
fall in blood pressure. And this fall was maximized if the patient had been previously 
submitted to sodium depletion by diuretics or low salt diet, which might produce only 
a small blood pressure fall by itself, but rendered the hypertension RAS-dependent 
and far more responsible to RAS blockade.
I S C H E M I C  C A R D I O M Y O P A T H Y  A N D  H E A R T  F A I L U R E
In parallel, we had found that excess angiotensin II, either exogenous, in experi-
mental animals, or endogenous, in various clinical settings, could produce significant 
cardiac and renal tissue damage, because the vasculature of these organs is particularly 
sensitive to the constricting effects of angiotensin. 3 In particularly, angiotensin excess 
was shown to produce widespread foci of necrosis and scarring of the myocardium, 
leading to replacement of myocardial tissue by fibrotic tissue, eventually progressing 
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to ischemic cardiomyopathy and heart failure.
Treatment of congestive heart failure with saralasin or 
with teprotide (both suitable for intravenous use only, in acute 
clinical experiments) resulted in significant hemodynamic 
improvements in terms of increased cardiac output, decreased 
peripheral arterial resistance, decreased heart rate, increased 
coronary blood flow and diminished myocardial oxygen con-
sumption. These small clinical trials offered the “proof of 
concept” in support of the notion that blockade of the RAS 
is beneficial in the treatment of ischemic cardiomyopathy and 
heart failure. This concept formed the basis for subsequent 
large randomized long-term outcome trials with oral ACEIs 
or ARBs, such as the HOPE, EUROPA, LIFE, CHARM, etc, 
which have now established treatment with an ACEI or ARB 
as mandatory therapy for patients with ischemic heart disease, 
as well as congestive or chronic heart failure.4-9
It is now universally accepted that initiation of RAS-
suppressing therapy with an ACEI or ARB in patients with 
multiple cardiovascular risk factors, not necessary including 
hypertension, offers long-term protection from ischemic heart 
disease, diastolic and systolic cardiac dysfunction, arrhythmias, 
as well as protection from renal insufficiency, cerebrovascular 
accidents and new onset type 2 diabetes mellitus.
G E N O M I C S
The molecular events triggered by angiotensin excess and 
leading to these complications are still poorly understood. We 
have conducted a number of genomic analyses on tissues of 
target organs from animals exposed to exogenous angiotensin 
excess using either the microarray technique (which reveals 
changes in expression of selected candidate genes placed on 
the microarray chips), or the serial analysis of gene expression 
(SAGE) technique, which does not require a priori knowledge 
of genes. The former revealed significant changes in expres-
sion of various genes related to the structure and function of 
cardiomyocytes, including growth factors, enzymes, receptors, 
etc. The latter revealed among others, a striking increase in 
expression of a hitherto unknown gene, the cardiomyopathy 
associated 3 (Cmya 3) gene which we were able to sequence and 
characterize, but whose product(s) remain still unknown.10
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